And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…

CVS Caremark will return the Eliquis blood thinner to its formulary, reversing a decision that sparked protests from physicians and patients.

Enanta Pharmaceuticals filed a lawsuit alleging the Pfizer Covid-19 pill violates a patent for its own Covid drug still in development.

The European Commission is investigating whether Vifor Pharma disparaged a rival treatment to its blockbuster drug for iron deficiency.

Good morning, everyone, and welcome to another working week, although today is actually a holiday on this side of the pond. So consider this something of a bonus feature. If nothing else, this is an opportunity to take a moment to quickly catch up on

The FTC put drugmakers and pharmacy benefit managers on notice that the agency will “ramp up enforcement” of any “illegal bribes and rebate schemes.”

Starting in 2015, a whistleblower lawsuit alleges CVS Health coordinated an effort to prevent consumers from obtaining low-cost generics.

A FDA advisory panel is scheduled to vote Wednesday whether Covid-19 vaccines should be cleared for use in children as young as 6 months old.

EU governments are intensifying pressure on Covid-19 vaccine makers to renegotiate contracts, warning millions of shots that are no longer needed could go to waste.

At a WTO conference on a response to the pandemic, the issue generating the most debate is a highly controversial proposal to temporarily waive intellectual property rights for vaccines.

GSK will apply for approval for its RSV vaccine for older adults, after reporting data showing the shot is the first to work in adults over 60 in a 25,000-volunteer…

The FDA needs to review changes to the manufacturing process used by Novavax before it can authorize the company’s Covid-19 vaccine.

A FDA expert panel voted overwhelmingly to recommend the agency issue an emergency use authorization for the Novavax Covid-19 vaccine.

A FDA advisory panel is set to scrutinize the Novavax Covid-19 vaccine after months of delays and an agency review that found the shots effective but raised a safety concern.

In results called unprecedented, an experimental GSK treatment shrank locally advanced rectal cancer until it was undetectable in all 14 patients in a clinical trial.

Bristol Myers Squibb agreed to buy Turning Point Therapeutics to deepen its position in lung-cancer treatments.

The biotech malaise has left more than 200 public companies running a business that is worth less than the cash they have in the bank.

Drugmakers and patient advocacy groups have aggressively lobbied for coverage of weight-loss drugs, but the status quo has not budged.

Looking to bolster its vaccines business with new technology, GSK is buying Affinivax in a transaction worth up to $3.3 billion.

The White House announced steps to make the Pfizer antiviral pill Paxlovid more accessible as it projects Covid-19 infections will continue to spread this summer.

Teva and Allergan reached a settlement worth $161.5 million to resolve claims the companies fueled an opioid epidemic in West Virginia.

Pfizer plans to provide nearly two dozen patent-protected medicines and vaccines at not-for-profit prices to 45 poor countries.

Bavarian Nordic is making more of a smallpox vaccine typically stockpiled for biological warfare, as governments seek to offer protection against monkeypox.

Pfizer and BioNTech expect to complete their submission for emergency authorization of their Covid-19 vaccine for children under 5 this week.

Covid-19 vaccine makers may find shelter from patent lawsuits under a legal theory Moderna is floating.

Moderna chair Noubar Afeyan launched an unflinching defense of the board’s executive hiring process after it was forced to fire its new chief financial officer last week.

CMS head Chiquita Brooks-LaSure says the agency expects to keep covering drugs that the FDA approves through its fast-track accelerated approval pathway, despite its recent decision on Biogen's Aduhelm.

The top executive at McKinsey appeared for the first time before Congress to answer for the consulting firm’s role in fanning the opioid crisis.

Rite Aid was ordered to pay nearly $123 million to Humana for allegedly seeking inflated reimbursements for prescription drugs.

The Biden administration announced a series of initiatives aimed at increasing the use of antiviral pills to treat Covid-19, with a focus on Pfizer's Paxlovid.